Gianluca Carlesso

US Patent:

20050008572, Jan 13, 2005

Filed:

Apr 28, 2004

Appl. No.:

10/833370

Inventors:

Ales Prokop - Nashville TN, US
Jeffrey Davidson - Nashville TN, US
Gianluca Carlesso - Nashville TN, US
David Roberts - Bethesda MD, US

International Classification:

A61K009/14
A61K049/00

US Classification:

424009600, 424489000

Abstract:

The present invention provides a series of biocompatible, nanoparticulate formulations that are designed to retain and deliver peptides such as anti-angiogenic factors over an extended time course. The nanoparticles can be targeted to a cell or tissue by targeting ligands crosslinked or conjugated to the corona of the nanoparticles. In addition to selective targeting, the nanoparticles also may perform noninvasive imaging using bioluminescence and/or magnetic resonance imaging via a contrast agent in the core of the nanoparticle. Also provided are methods of delivering to and, optionally, imaging of a cell or tissue. Furthermore, methods of producing the nanoparticles in batch or continous mode via simple mixing or micromixing.

US Patent:

20050266090, Dec 1, 2005

Filed:

May 10, 2005

Appl. No.:

11/125438

Inventors:

Ales Prokop - Nashville TN, US
Jeffrey Davidson - Nashville TN, US
Gianluca Carlesso - Nashville TN, US
David Roberts - Bethesda MD, US

International Classification:

A61K009/14

US Classification:

424489000

Abstract:

The present invention provides biocompatible, low molecular weight nanoparticulate formulations that are designed to retain and deliver therapeutics over an extended time course. The therapeutic may be conjugated or adsorbed to the periphery of the corona or conjugated to a core polymer. The nanoparticles comprise targeting ligands also conjugated or adsorbed to the periphery of the corona and/or a contrast agent in the core of the nanoparticle. As such, methods of selective targeting and/or methods of noninvasive imaging using bioluminescence and/or magnetic resonance imaging. Also provided are methods of delivering to and, optionally, imaging of a cell or tissue. Further provided are methods of producing the nanoparticles in batch or continuous mode via simple mixing or laminar flow.

US Patent:

20080279851, Nov 13, 2008

Filed:

May 7, 2008

Appl. No.:

12/116512

Inventors:

Anthony COYLE - Washington DC, US
Yihong Yao - Boyds MD, US
Bahija Jallal - Potomac MD, US
Gianluca Carlesso - Rockville MD, US
Michael Bowen - Rockville MD, US

Assignee:

Medlmmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
C07K 16/00
A61P 29/00
A61P 37/02
C07H 21/00

US Classification:

4241331, 5303873, 536 2353

Abstract:

The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

US Patent:

20110243929, Oct 6, 2011

Filed:

Dec 17, 2010

Appl. No.:

12/971469

Inventors:

Anthony COYLE - Boston MA, US
Yihong Yao - Boyds MD, US
Bahija Jallal - Potomac MD, US
Gianluca Carlesso - Rockville MD, US
Michael Bowen - Rockville MD, US

Assignee:

Medlmmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
C07K 16/18
C07H 21/04
C12N 15/63
C12N 5/10
A61P 37/06

US Classification:

4241331, 5303873, 536 2353, 4353201, 435325

Abstract:

The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

US Patent:

20110293605, Dec 1, 2011

Filed:

Nov 12, 2009

Appl. No.:

13/128499

Inventors:

Hasige Sathish - Germantown MD, US
Ambarish Shah - Boyds MD, US
Gianluca Carlesso - Rockville MD, US
Tracy Delaney - Montgomery Village MD, US

International Classification:

A61K 39/395
A61P 29/00
A61P 43/00
A61P 37/06

US Classification:

4241331

Abstract:

Herein described are liquid formulations of antibodies and biologically active fragments thereof that specifically bind to a human ICOS polypeptide, exhibit increased in vivo ADCC activity and undergo reversible self-association in solution.

US Patent:

20130142783, Jun 6, 2013

Filed:

Sep 6, 2012

Appl. No.:

13/605468

Inventors:

Anthony COYLE - Boston MA, US
Yihong Yao - Boyds MD, US
Bahija Jallal - Potomac MD, US
Gianluca Carlesso - Rockville MD, US
Michael Bowen - Rockville MD, US

Assignee:

MEDIMMUNE, LLC - Gaithersburg MD

International Classification:

C07K 16/28

US Classification:

4241331, 5303873, 536 2353, 4353201, 435328

Abstract:

The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

US Patent:

20040136961, Jul 15, 2004

Filed:

Jun 30, 2003

Appl. No.:

10/609722

Inventors:

Ales Prokop - Nashville TN, US
Jeffrey Davidson - Nashville TN, US
Gianluca Carlesso - Nashville TN, US
Derya Unutmaz - Nashville TN, US

International Classification:

A61K048/00

US Classification:

424/093200

Abstract:

The present invention provides compositions comprising a water-based core solution and a water-based corona solution surrounding the core solution. The compositions comprise polyanionic polymers and salts and polycationic polymers and cations and is useful for adenoviral delivery of a gene or delivery of another drug. The compositions may be nanoparticulate, microcapsular or form a polymeric sheet. Also provided are methods of use for the compositions.

US Patent:

20220251204, Aug 11, 2022

Filed:

Dec 14, 2021

Appl. No.:

17/550219

Inventors:

- Gaithersburg MD, US
Changshou GAO - Gaithersburg MD, US
Godfrey RAINEY - Gaithersburg MD, US
Michelle MORROW - Cambridge, GB
Claire Louise DOBSON - Cambridge, GB
Stacey DRABIC - Gaithersburg MD, US
Darren SCHOFIELD - Cambridge, GB
Gianluca CARLESSO - Gaithersburg MD, US
Kristen POLLIZZI - Gaithersburg MD, US
Yariv MAZOR - Gaithersburg MD, US
Michael OBERST - Gaithersburg MD, US
Scott A. HAMMOND - Gaithersburg MD, US
Brian LOBO - Gaithersburg MD, US
Prakash MANIKWAR - Gaithersburg MD, US
Jonathan SEAMAN - Cambridge, GB
Simon DOVEDI - Cambridge, GB
Ronald HERBST - Gaithersburg MD, US

International Classification:

C07K 16/28

Abstract:

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.